Category: ALung Technologies Inc.Syndicate content

FDA panel: 30-year-old ECMO therapy should be reclassified to lower-risk Class II

September 13, 2013 by Ingrid Mezo

An FDA advisory panel recommends reclassifying extracorporeal membrane oxygenator therapy from the highest-risk category to the less-risky Class II designation.

FDA panel: 30-year-old ECMO therapy should be reclassified to lower-risk Class II

An FDA panel yesterday recommended that the FDA reclassify membrane lung for long-term pulmonary support systems, or so-called extracorporeal membrane oxygenator circuits and accessories, from the highest-risk Class III category to the less burdensome Class II, with special controls.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

ALung breathes easy with $16M funding round

September 11, 2013 by Brad Perriello

ALung Technologies raises a nearly $16 million Series B1 round for its Hemolung respiratory assist device.

ALung breathes easy with $16M funding round

ALung Technologies said it raised a $15.8 million Series B1 round it plans to use to accelerate the commercialization of its Hemolung respiratory assist device.

The Pittsburgh-based medical device company said the round was led by Allos Ventures and included West Capital Partners, Birchmere Ventures, BlueTree Capital Group, PLSG Accelerator Fund, Smithfield Trust Company and several private investors.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

ALung nears close of $17M equity funding round

July 22, 2013 by Arezu Sarvestani

ALung inches closer to topping off a $17 million fundraising round, with less than $2.3 million left to raise.

ALung Technologies logo

Pennsylvania medical device maker ALung Technologies is nearing the close of a $17 million equity funding round with about $14.7 million raised so far among 48 unnamed investors, according to an SEC filings.

The new report updated a fundraising effort that began in late March 2013, and ALung reported last month that it had hit the $9.5 million mark in the raise. Now it's got about 2.3 million left before putting a bow on this round.

ALung pulls in $9.5M, aims for $7.5M more

June 21, 2013 by Brad Perriello

ALung pulls in $9.5 million in an equity funding round it hopes will eventually bring in a total of $17 million for its Hemolung respiratory assist system.

ALung pulls in $9.5M, aims for $7.5M more

ALung Technologies raised $9.5 million of a hoped-for $17 million for its Hemolung respiratory assist system, according to a regulatory filing.

The Pittsburgh-based medical device company is aiming to get the Hemolung device on the market here and in China.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

ALung pursues Chinese approval for Hemolung

May 22, 2013 by Sony Salzman

ALung Technologies says it's going for a Chinese regulatory nod for its Hemolung respiratory assist device.

ALung Technologies and Curative Medical go after Chinese markets

ALung Technologies said it's pursuing approval from Chinese regulatory authorities for its Hemolung respiratory assist system.

The Pittsburgh-based medical device company said it inked a deal with Curative Medical to seek approval for the Hemolung device from the China Food & Drug Administration.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

AngioDynamics details $372M Navilyst buyout details | Wall Street Beat

February 8, 2012 by MassDevice staff

The $372 million buyout of Navilyst medical is expected to add 8 cents per share to AngioDynamics' books during fiscal 2013; also, Orasi Medical closes up shop; Becton, Dickinson reveals medical device tax impact; Abiomed hits 52-week high; analysts' ups and downs; and the MassDevice.com Funding Roundup.

MassDevice.com Wall Street Beat

Financial projections from AngioDynamics (NSDQ:ANGO) about its $372 million deal to acquire Navilyst Medical show that it expects to reap some significant rewards from the merger over the short and long terms.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp